Entrada Therapeutics Total Current Liabilities

Entrada Therapeutics (TRDA) currently reports a total current liabilities of $21M as of June 2026. That compares with $20M in the prior-year period — up 7.9% year over year. Use the charts on this page to explore Entrada Therapeutics's total current liabilities history and peer comparisons.

Entrada Therapeutics's total current liabilities increased from $20M to $21M — a 7.9% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Entrada Therapeutics reported $21M in total current liabilities as of June 2026. That compares with $20M in the prior-year period — up 7.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $21M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Entrada Therapeutics, and consider following TRDA for alerts when major investors trade the stock.